Agrenvec is a European biotech specialized in plant production of mammalian recombinant proteins and antibodies for the R&D market.
Agrenvec is focused on development, manufacture and marketing, of products and services for the R&D and Industrial markets. Our Company owns a patented technology platform allowing us a high-throughput production of fully active recombinant proteins with complex 3D structure. Our proteins are 100% animal free and minimum purity of 97%.
This technology is based on the use of vectors derived from plant viruses.
Our production system, compared to transgenic plants, is more efficient and flexible, faster and cheaper. Its scaling up is easier and linear; we obtain from milligrams to kilograms of the protein of interest.
Agrenvec has developed unique purification protocols that combined with our technology platform enable us to produce recombinant proteins very competitively. We have accumulated a deep know-how in industrial production of recombinant proteins and antibodies. After several years of experience we control the whole value chain, from the bench to the final product, thanks to our highly qualified team.
Agrenvec is client-focused, so we adapt to our customer needs in all our projects.
Some of our projects have been co-founded by the Spanish Ministry of Science, and other public organizations, such as Innovation Department of Madrid Regional Government, CDTI, ENISA, Genoma España.
PROTEIN PRODUCTION TECHNOLOGY
Transient vector expresión (non- transgenic plants) for protein production
ANIMAL FREE PRODUCTS PRODUCED IN NON-TRANSGENIC PLANTS
a) RECOMBINANT PROTEINS
*
Proteins with high structural complexity with post-translational modifications
*
Active
*
Animal-free: Eliminates the risk of exposure to retroviruses and other agents that may be present in animal derived material. No mammalian protein contamination makes our products ideal for cell culture work
*
Endotoxin levels two orders of magnitude lower than other expression systems. Extremely low endotoxin levels as compared to recombinant proteins produced in bacterial systems. This is especially important in animal experiments among others. Perfect reagent for Stem Cell Culture
*
High added-value because they are difficult or impossible to produce in bacteria. Do not produce inclusion bodies (unlike bacteria, therefore is not necessary to denature – renature, with clear loss of activity)
*
≥ 97% Purity
b) POLYCLONAL ANTIBODIES
*
Generated against plant recombinant proteins (antigen)
*
Very low background signal / Very high specificity (Clean Antibodies)
*
Very high sensitivity (< 1ng/100µl sampler in alkaline phosphatase at Indirect ELISA)
*
No cross-reactivity with other mammalian proteins
*
Only 1h incubation as a primary antibody in Western Blot, allowing the development of a WB assay in less than one working day (all figures in the data sheets have been developed with alkaline phosphatase)
PRODUCTS
Recombinant Proteins
Portfolio
Characteristics
*
r Human TGF β 2 Active
*
High complex folding structure
*
r Human TGF β 3 Active
*
Eukaryotic protein modification machinery
*
r Human TGF β 2
*
Animal free
*
r Human TGF β 3
*
Active
*
r Human TFPI-2 Domain 1 Active
*
≥97% pure
*
r Human ACTIVIN A Active
*
Cell culture grade
*
r Human ACTIVIN A
*
Extremely Low Endotoxins Level
*
r Human LXR β-LBD
Clean Antibodies
Portfolio of Rabbit Polyclonal to
Characteristics
*
Human TFPI-2
*
No vertebrate background signal
*
Human INTERFERON α 2a
*
1 hour primary antibody incubation in Western Blot Assay
*
Human HGH (Somatotropin)
*
High sensitivity. Detection under 1ng by indirect ELISA